Novel Combination Therapy for Extensively Drug-Resistant <i>Acinetobacter baumannii</i> Necrotizing Pneumonia Complicated by Empyema: A Case Report.

Open Forum Infect Dis · 2022 · PMC8946682 · PMID 35350174

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a statistical trendno p-value reported

SUL-DUR met the primary end point of 28-day all-cause mortality showing noninferiority compared with colistin in a microbiologically modified intent-to-treat population, with a statistical trend toward lower mortality among patients who received SUL-DUR vs colistin (19% [12/63] vs 32.3% [20/62], respectively).

also in 2,681 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.